Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3

array:24 ["pii" => "S2013251416000079" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2016.01.006" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "101" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2015" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Nefrologia (English Version). 2016;36:72-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4374 "formatos" => array:3 [ "EPUB" => 298 "HTML" => 3507 "PDF" => 569 ] ] "itemSiguiente" => array:18 [ "pii" => "S201325141500111X" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2015.08.005" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "86" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "cor" "cita" => "Nefrologia (English Version). 2016;36:75-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3987 "formatos" => array:3 [ "EPUB" => 320 "HTML" => 3064 "PDF" => 603 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Methylmalonic acidemia with emergency hypertension" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "75" "paginaFinal" => "76" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Acidemia metilmalónica con hipertensión de emergencia" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Bahareh Yaghmaei, Parastoo Rostami, Farnaz Najmi Varzaneh, Behdad Gharib, Behnaz Bazargani, Nima Rezaei" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Bahareh" "apellidos" => "Yaghmaei" ] 1 => array:2 [ "nombre" => "Parastoo" "apellidos" => "Rostami" ] 2 => array:2 [ "nombre" => "Farnaz Najmi" "apellidos" => "Varzaneh" ] 3 => array:2 [ "nombre" => "Behdad" "apellidos" => "Gharib" ] 4 => array:2 [ "nombre" => "Behnaz" "apellidos" => "Bazargani" ] 5 => array:2 [ "nombre" => "Nima" "apellidos" => "Rezaei" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325141500111X?idApp=UINPBA000064" "url" => "/20132514/0000003600000001/v2_201703300133/S201325141500111X/v2_201703300133/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2013251416000250" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2016.02.004" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "89" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Nefrologia (English Version). 2016;36:69-71" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5736 "formatos" => array:3 [ "EPUB" => 321 "HTML" => 4671 "PDF" => 744 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor – Brief Case Reports" "titulo" => "Ibuprofen-induced acute interstitial nephritis in the paediatric population" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "69" "paginaFinal" => "71" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nefritis intersticial aguda por ibuprofeno en población pediátrica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1951 "Ancho" => 1653 "Tamanyo" => 179260 ] ] "descripcion" => array:1 [ "en" => "Changes over time in urea and creatinine levels." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ana Belen Martínez-López, Olalla Álvarez Blanco, Augusto Luque de Pablos, María Dolores Morales San-José, Ana Rodríguez Sanchez de la Blanca" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Ana Belen" "apellidos" => "Martínez-López" ] 1 => array:2 [ "nombre" => "Olalla" "apellidos" => "Álvarez Blanco" ] 2 => array:2 [ "nombre" => "Augusto" "apellidos" => "Luque de Pablos" ] 3 => array:2 [ "nombre" => "María Dolores" "apellidos" => "Morales San-José" ] 4 => array:2 [ "nombre" => "Ana" "apellidos" => "Rodríguez Sanchez de la Blanca" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0211699515001411" "doi" => "10.1016/j.nefro.2015.09.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001411?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000250?idApp=UINPBA000064" "url" => "/20132514/0000003600000001/v2_201703300133/S2013251416000250/v2_201703300133/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "72" "paginaFinal" => "75" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Emanuel Ferreira, Nuno Oliveira, Maria Marques, Luís Francisco, Ana Santos, Armando Carreira, Mário Campos" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Emanuel" "apellidos" => "Ferreira" "email" => array:1 [ 0 => "emanuelfeferreira@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Nuno" "apellidos" => "Oliveira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Maria" "apellidos" => "Marques" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Luís" "apellidos" => "Francisco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Ana" "apellidos" => "Santos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Armando" "apellidos" => "Carreira" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Mário" "apellidos" => "Campos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Hematología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospitais da Universidade de Coimbra, Coimbra, Portugal" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral., Rua do Buxo, lote 17, 3040-792 Coimbra, Portugal. Tel.: +351 916699039." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Eculizumab para el tratamiento de un síndrome urémico hemolítico atípico con mutaciones en los factores I y C3 del sistema del complemento" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3462 "Ancho" => 2390 "Tamanyo" => 405309 ] ] "descripcion" => array:1 [ "en" => "Clinical course: laboratory data and treatment. Corticosteroid therapy was started with intravenous administration of methylprednisolone (1000mg/day for 3 days) followed by oral prednisolone and an initial dosage of 60mg/day. This dosage was maintained until the 53rd day after admission, with posterior tapering. Rituximab (arrows) was administered at a dose of 600mg (375mg/m2) on the 27th, 34th, 41st and 48th days after admission. Cyclophosphamide (arrowhead) was administered in a single dose of 1000mg on the 61st day after admission (2nd day after readmission). Eculizumab was administered at a dose of 900mg for a week for 4 weeks, started on the 158th day after admission, followed by a dosage of 1200mg 1 week later an then a maintenance dose of 1200mg every 2 weeks. This dosage is still being continued. We performed a total of 79 plasma exchange sessions. The last three laboratorial test results were done on the 270th, 340th and 466th days following first admission." ] ] ] "textoCompleto" => "Atypical hemolytic-uremic syndrome (aHUS) is a rare, life-threatening complement-mediated thrombotic microangiopathy.<a class="elsevierStyleCrossRef" href="#bib0055">1</a> Approximately half of cases have mutations in complement proteins but only 12% have 2 or more mutations.<a class="elsevierStyleCrossRef" href="#bib0060">2</a> Eculizumab is nowadays considered first-line therapy for aHUS.<a class="elsevierStyleCrossRef" href="#bib0065">3</a>A 33-year-old female with unremarkable past medical history presented with a 3-day history of decreased urine output. Physical examination showed hypertension (160/90mmHg) and lower limbs edema. Investigations revealed an acute thrombotic microangiopathy (ATM), hematuria and nephrotic proteinuria (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Daily plasmapheresis (PMP) was started immediately.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Investigations for secondary causes of ATM revealed a low ADAMTS 13 activity, decreased complement C4, C3, C1q and C2 levels and positive serum cryoglobulins (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Considering the hypothesis of an autoimmune disorder, we started 3 daily pulses of 1000mg methylprednisolone followed by oral prednisolone.PMP was stopped on the eighteenth day of admission (D18) due to normal platelet count during 3 consecutive days (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). On the D19 a renal biopsy was made. It showed a “thrombotic microangiopathy with acute tubular necrosis” and “deposition of IgM, C3 and C1q in the capillary wall”. Due to increased hemolytic activity, PMP was resumed on the D21. On the D27, rituximab was started to enhance immunosuppression. PMP was stopped on the D35 based on the absence of schistocytosis, hemoglobin stability and lactate dehydrogenase (LDH) normalization.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>On the D50, LDH was high but hemoglobin and platelet count were stable. A state of compensated hemolysis was assumed and the patient was discharged home.Ten days later she was readmitted due to increased hemolytic activity (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). PMP was resumed and 1000mg cyclophosphamide was given. At that time ADAMTS13 and complement C4 levels were normal but complement C3 levels remained low.A genetic screening for mutations in complement regulatory proteins was made. Two mutations were found in factor I (C. 452 A>G, pASN 151 Ser) and C3 (C193 A>C, pLys 65 Gin) proteins. The process of eculizumab acquisition was lengthy, wherefore this therapy was started only on the 98th day after readmission. At that moment we were performing one PMP session/week, LDH remained high (859U/L) and moderate renal dysfunction (creatinine 2.08mg/dL and urea 60mg/dL) and nephrotic proteinuria persisted (5.2g/24h). Eculizumab was administered at a dose of 900mg per week for 4 weeks followed by subsequent doses of 1200mg every 2 weeks since the 5th week. Complete hematologic remission was attained 2 days after eculizumab initiation. The patient was discharged home on the 105th day after readmission. Four weeks later, proteinuria was only 0.6g/24h.Currently, 10 months after first infusion, the patient remains under biweekly administration of eculizumab. Hematologic remission persists and there is a significant recover of renal function (urea 43mg/dL, creatinine 1.27mg/dL).Complement factor I (CFI) and C3 mutations account for 10% and 4% of the overall aHUS-associated mutations, respectively.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> C3 mutations are among the ones with the poorest prognosis: 75% risk of death or end stage renal failure (ESRF) at 3–5 years follow up and 50% risk of recurrence.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> CFI mutations have a 50–60% risk of death and ESRF at 3–5 years follow up and 10–30% risk of recurrence.<a class="elsevierStyleCrossRef" href="#bib0065">3</a>Both mutations present in our patient were previously reported.<a class="elsevierStyleCrossRefs" href="#bib0070">4,5</a> The p.Asn151Ser mutation causes a quantitative deficiency of factor I<a class="elsevierStyleCrossRef" href="#bib0070">4</a> and the p.Lys65Gin mutation weakens the affinity of C3b to complement factor H.<a class="elsevierStyleCrossRef" href="#bib0075">5</a>Despite the growing importance of eculizumab,<a class="elsevierStyleCrossRefs" href="#bib0080">6,7</a> PMP remains the mainstay of treatment while waiting for the immunoglobulin.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> Nonetheless, its benefit depends on the underlying genetic defect – only 25% and 57% of those with CFI and C3 mutations, respectively, achieve remission.<a class="elsevierStyleCrossRef" href="#bib0090">8</a> In our patient, PMP was critical to prevent further progression of renal failure and the development of other systemic involvement. However, as described by Loirat,<a class="elsevierStyleCrossRef" href="#bib0060">2</a> it was unable to achieve complete and sustained remission.In our case, the confounding presence of low ADAMTS13, C4, C2 and C1q levels, the presence of cryoglobulins and the existence of immune deposits in the glomerular capillary wall led to the misdiagnosis of a thrombotic thrombocytopenic purpura secondary to an autoimmune disease. It explains the preference for glucocorticoids, rituximab and cyclophosphamide in relation to eculizumab.<a class="elsevierStyleCrossRef" href="#bib0095">9</a>Eculizumab is nowadays considered first-line therapy for aHUS.<a class="elsevierStyleCrossRef" href="#bib0065">3</a> It is a humanized monoclonal immunoglobulin IgG that targets C5 and blocks the uncontrolled generation of the cytotoxic membrane attack complex.<a class="elsevierStyleCrossRef" href="#bib0100">10</a> When we started Eculizumab, our patient was still PMP dependent despite the 79 PMP sessions. Contrariwise, complete hematologic remission was attained two days after first infusion and a remarkable recover of renal function and reduction of proteinuria was evident. These findings reinforce the benefits of eculizumab in aHUS, even in cases of severe renal involvement.In conclusion, our case highlights the diagnostic challenge of aHUS and emphasizes the notion that isolated PMP is no longer the best therapeutic option in aHUS, in which cases a prompt switch to eculizumab is mandatory.The authors declare that they have no conflicts of interest related to the contents of this article." "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, et al. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia. 2016;36:72–75." ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3462 "Ancho" => 2390 "Tamanyo" => 405309 ] ] "descripcion" => array:1 [ "en" => "Clinical course: laboratory data and treatment. Corticosteroid therapy was started with intravenous administration of methylprednisolone (1000mg/day for 3 days) followed by oral prednisolone and an initial dosage of 60mg/day. This dosage was maintained until the 53rd day after admission, with posterior tapering. Rituximab (arrows) was administered at a dose of 600mg (375mg/m2) on the 27th, 34th, 41st and 48th days after admission. Cyclophosphamide (arrowhead) was administered in a single dose of 1000mg on the 61st day after admission (2nd day after readmission). Eculizumab was administered at a dose of 900mg for a week for 4 weeks, started on the 158th day after admission, followed by a dosage of 1200mg 1 week later an then a maintenance dose of 1200mg every 2 weeks. This dosage is still being continued. We performed a total of 79 plasma exchange sessions. The last three laboratorial test results were done on the 270th, 340th and 466th days following first admission." ] ] 1 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "tablatextoimagen" => array:2 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">On admission</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hemoglobin (g/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12–16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">White-cell count (×103/mm3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4–10 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Platelet count (×103/mm3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">150–400 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral blood smear<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 schistocytes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2 schistocytes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Haptoglobin (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><0.08 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.3–2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Direct coombs tests \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urea (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">114 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15–38 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatinine (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.52–1.04 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sodium (mmol/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">135 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">137–145 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Potassium (mmol/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.5–5.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lactate dehydrogenase (U/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2827 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">313–618 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">c-Reactive protein (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><1.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">URINALYSIS</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Protein (mg/dL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Leukocytes (/HPF) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><5/c \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Red blood cells (/HPF) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><2/c \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urinary protein to creatinine ratio (mg/mg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><0.15 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1381851.png" ] ] 1 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Additional studies</th></tr><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C3 (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.9–1.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C4 (g/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.02 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.1–0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CH50 (U/mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23–46 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118–244 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q Inhibitor (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">197 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">180/320 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C2 (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14–25 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ADAMTS13 activity (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40–130 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anti-ADAMTS13 antibody (U/mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><15 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serum cryoglobulins \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Auto-immune antibodies<a class="elsevierStyleCrossRef" href="#tblfn0010">b</a>, Pregnancy test, SPE, Tumoral markers<a class="elsevierStyleCrossRef" href="#tblfn0015">c</a>, HIV, HBV, HCV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative/Normal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blood, urine and stool cultures \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Upper endoscopy, colonoscopy, cervical, thoracic and abdominopelvic CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Irrelevant changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1381850.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Peripheral blood smear was done to evaluate presence of erythrocyte fragmentation and is reported as schistocytes count in a microscopic field at 100× magnification." ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "Antinuclear antibodies, extractable nuclear antigens, anti-neutrophil cytoplasmic antibodies, glomerular basement membrane, rheumatoid factor, cyclic citrullinated peptide, anticardiolipin/anti-β2-glycoprotein, Lupus anticoagulant." ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "Carcinoembryonic antigen, carbohydrate antigen 19-9, α-fetoprotein, cancer antigen 125, neuron-specific enolase, NSE. Abbreviations: ADAMTS13; a disintegrin and metalloproteinase with a thrombospondin type 1 motif; member 13. CT; computerized tomography. HBV; hepatitis B virus. HCV; hepatitis C virus. HIV; human immunodeficiency virus. SPE; serum protein electrophoresis." ] ] ] "descripcion" => array:1 [ "en" => "Laboratorial results on admission and additional studies to establish the cause of the thrombotic microangiopathy." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of atypical uraemic syndrome in the era of eculizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "V. Fremeaux-Bacchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ckj/sfr177" "Revista" => array:6 [ "tituloSerie" => "Clin Kidney J" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "4" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26069738" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atypical hemolytic uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C. Loirat" 1 => "V. Frémeaux-Bacchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1750-1172-6-60" "Revista" => array:5 [ "tituloSerie" => "Orphanet J Rare Dis" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "60" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21902819" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Campistol" 1 => "M. Arias" 2 => "G. Ariceta" 3 => "M. Blasco" 4 => "M. Espinosa" 5 => "J.M. Grinyó" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3265/Nefrologia.pre2012.Nov.11781" "Revista" => array:6 [ "tituloSerie" => "Nefrologia" "fecha" => "2013" "volumen" => "33" "paginaInicial" => "27" "paginaFinal" => "45" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23364625" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Bienaime" 1 => "M.A. Dragon-Durey" 2 => "C.H. Regnier" 3 => "S.C. Nilsson" 4 => "W.H. Kwan" 5 => "J. Blouin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2009.472" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2010" "volumen" => "77" "paginaInicial" => "339" "paginaFinal" => "349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016463" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Volokhina" 1 => "D. Westra" 2 => "X. Xue" 3 => "P. Gros" 4 => "N. van de Kar" 5 => "L. van den Heuvel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00467-012-2183-z" "Revista" => array:6 [ "tituloSerie" => "Pediatr Nephrol" "fecha" => "2012" "volumen" => "27" "paginaInicial" => "1519" "paginaFinal" => "1524" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22669319" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Rathbone" 1 => "E. Kaltenthaler" 2 => "A. Richards" 3 => "P. Tappenden" 4 => "A. Bessey" 5 => "A. Cantrell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmjopen-2013-003573" "Revista" => array:5 [ "tituloSerie" => "BMJ Open" "fecha" => "2013" "volumen" => "3" "paginaInicial" => "e003573" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24189082" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M. Legendre" 1 => "C. Licht" 2 => "P. Muus" 3 => "L.A. Greenbaum" 4 => "S. Babu" 5 => "C. Bedrosian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1208981" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2013" "volumen" => "368" "paginaInicial" => "2169" "paginaFinal" => "2181" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23738544" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Noris" 1 => "J. Caprioli" 2 => "E. Bresin" 3 => "C. Mossali" 4 => "G. Pianetti" 5 => "S. Gamba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2215/CJN.02210310" "Revista" => array:7 [ "tituloSerie" => "Clin J Am Soc Nephrol" "fecha" => "2010" "volumen" => "5" "paginaInicial" => "1844" "paginaFinal" => "1859" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20595690" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109798005786" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "Available at: <span class="elsevierStyleInterRef" id="intr0005" href="http://www.uptodate.com/contents/treatment-and-prognosis-of-thrombotic-thrombocytopenic-purpura-hemolytic-uremic-syndromes-in-adults?source=search_result%26search=Treatment+of+thrombotic+thrombocytopenic+purpura-hemolytic+uremic+syndrome+in+adults%26selectedTitle=1~150">http://www.uptodate.com/contents/treatment-and-prognosis-of-thrombotic-thrombocytopenic-purpura-hemolytic-uremic-syndromes-in-adults?source=search_result&search=Treatment+of+thrombotic+thrombocytopenic+purpura-hemolytic+uremic+syndrome+in+adults&selectedTitle=1∼150#H30 [accessed 14.06.14]. [Updated 2014 May 14]" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.A. Kaplan" 1 => "J.N. George" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Uptodate" "fecha" => "2014" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eculizumab: a review of its use in atypical haemolytic uraemic syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40265-013-0147-7" "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2013" "volumen" => "73" "paginaInicial" => "2053" "paginaFinal" => "2066" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24249647" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003600000001/v2_201703300133/S2013251416000079/v2_201703300133/en/main.assets" "Apartado" => array:4 [ "identificador" => "35436" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003600000001/v2_201703300133/S2013251416000079/v2_201703300133/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000079?idApp=UINPBA000064"]

Statistics

Letter to the Editor

Eculizumab para el tratamiento de un síndrome urémico hemolítico atípico con mutaciones en los factores I y C3 del sistema del complemento

Emanuel Ferreiraa,

Corresponding author

emanuelfeferreira@gmail.com

Corresponding author at: Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral., Rua do Buxo, lote 17, 3040-792 Coimbra, Portugal. Tel.: +351 916699039.

, Nuno Oliveiraa, Maria Marquesa, Luís Franciscob, Ana Santosa, Armando Carreiraa, Mário Camposc

a Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal

b Servicio de Hematología, Centro Hospitalar e Universitário de Coimbra–Hospital Geral, Coimbra, Portugal

c Servicio de Nefrología, Centro Hospitalar e Universitário de Coimbra–Hospitais da Universidade de Coimbra, Coimbra, Portugal

Read

8234

Times
was read the article

2287

Total PDF

5947

Total HTML

Share statistics

 array:24 [
  "pii" => "S2013251416000079"
  "issn" => "20132514"
  "doi" => "10.1016/j.nefroe.2016.01.006"
  "estado" => "S300"
  "fechaPublicacion" => "2016-01-01"
  "aid" => "101"
  "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
  "copyrightAnyo" => "2015"
  "documento" => "simple-article"
  "crossmark" => 0
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "cor"
  "cita" => "Nefrologia &#40;English Version&#41;. 2016;36:72-5"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4374
    "formatos" => array:3 [
      "EPUB" => 298
      "HTML" => 3507
      "PDF" => 569
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S201325141500111X"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2015.08.005"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "86"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "cor"
    "cita" => "Nefrologia &#40;English Version&#41;. 2016;36:75-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3987
      "formatos" => array:3 [
        "EPUB" => 320
        "HTML" => 3064
        "PDF" => 603
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
      "titulo" => "Methylmalonic acidemia with emergency hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "75"
          "paginaFinal" => "76"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Acidemia metilmal&#243;nica con hipertensi&#243;n de emergencia"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Bahareh Yaghmaei, Parastoo Rostami, Farnaz Najmi Varzaneh, Behdad Gharib, Behnaz Bazargani, Nima Rezaei"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Bahareh"
              "apellidos" => "Yaghmaei"
            ]
            1 => array:2 [
              "nombre" => "Parastoo"
              "apellidos" => "Rostami"
            ]
            2 => array:2 [
              "nombre" => "Farnaz Najmi"
              "apellidos" => "Varzaneh"
            ]
            3 => array:2 [
              "nombre" => "Behdad"
              "apellidos" => "Gharib"
            ]
            4 => array:2 [
              "nombre" => "Behnaz"
              "apellidos" => "Bazargani"
            ]
            5 => array:2 [
              "nombre" => "Nima"
              "apellidos" => "Rezaei"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S201325141500111X?idApp=UINPBA000064"
    "url" => "/20132514/0000003600000001/v2_201703300133/S201325141500111X/v2_201703300133/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2013251416000250"
    "issn" => "20132514"
    "doi" => "10.1016/j.nefroe.2016.02.004"
    "estado" => "S300"
    "fechaPublicacion" => "2016-01-01"
    "aid" => "89"
    "copyright" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
    "documento" => "simple-article"
    "crossmark" => 0
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "Nefrologia &#40;English Version&#41;. 2016;36:69-71"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5736
      "formatos" => array:3 [
        "EPUB" => 321
        "HTML" => 4671
        "PDF" => 744
      ]
    ]
    "en" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor &#8211; Brief Case Reports</span>"
      "titulo" => "Ibuprofen-induced acute interstitial nephritis in the paediatric population"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "69"
          "paginaFinal" => "71"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Nefritis intersticial aguda por ibuprofeno en poblaci&#243;n pedi&#225;trica"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1951
              "Ancho" => 1653
              "Tamanyo" => 179260
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Changes over time in urea and creatinine levels&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Belen Mart&#237;nez-L&#243;pez, Olalla &#193;lvarez Blanco, Augusto Luque de Pablos, Mar&#237;a Dolores Morales San-Jos&#233;, Ana Rodr&#237;guez Sanchez de la Blanca"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ana Belen"
              "apellidos" => "Mart&#237;nez-L&#243;pez"
            ]
            1 => array:2 [
              "nombre" => "Olalla"
              "apellidos" => "&#193;lvarez Blanco"
            ]
            2 => array:2 [
              "nombre" => "Augusto"
              "apellidos" => "Luque de Pablos"
            ]
            3 => array:2 [
              "nombre" => "Mar&#237;a Dolores"
              "apellidos" => "Morales San-Jos&#233;"
            ]
            4 => array:2 [
              "nombre" => "Ana"
              "apellidos" => "Rodr&#237;guez Sanchez de la Blanca"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0211699515001411"
        "doi" => "10.1016/j.nefro.2015.09.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699515001411?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000250?idApp=UINPBA000064"
    "url" => "/20132514/0000003600000001/v2_201703300133/S2013251416000250/v2_201703300133/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>"
    "titulo" => "Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "72"
        "paginaFinal" => "75"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Emanuel Ferreira, Nuno Oliveira, Maria Marques, Lu&#237;s Francisco, Ana Santos, Armando Carreira, M&#225;rio Campos"
        "autores" => array:7 [
          0 => array:4 [
            "nombre" => "Emanuel"
            "apellidos" => "Ferreira"
            "email" => array:1 [
              0 => "emanuelfeferreira&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Nuno"
            "apellidos" => "Oliveira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Maria"
            "apellidos" => "Marques"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Lu&#237;s"
            "apellidos" => "Francisco"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Ana"
            "apellidos" => "Santos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Armando"
            "apellidos" => "Carreira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "M&#225;rio"
            "apellidos" => "Campos"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#44; Coimbra&#44; Portugal"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#44; Coimbra&#44; Portugal"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospitais da Universidade de Coimbra&#44; Coimbra&#44; Portugal"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author at</span>&#58; Servicio de Nefrolog&#237;a&#44; Centro Hospitalar e Universit&#225;rio de Coimbra&#8211;Hospital Geral&#46;&#44; Rua do Buxo&#44; lote 17&#44; 3040-792 Coimbra&#44; Portugal&#46; Tel&#46;&#58; &#43;351 916699039&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Eculizumab para el tratamiento de un s&#237;ndrome ur&#233;mico hemol&#237;tico at&#237;pico con mutaciones en los factores I y C3 del sistema del complemento"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3462
            "Ancho" => 2390
            "Tamanyo" => 405309
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical course&#58; laboratory data and treatment&#46; Corticosteroid therapy was started with intravenous administration of methylprednisolone &#40;1000<span class="elsevierStyleHsp" style=""></span>mg&#47;day for 3 days&#41; followed by oral prednisolone and an initial dosage of 60<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; This dosage was maintained until the 53rd day after admission&#44; with posterior tapering&#46; Rituximab &#40;arrows&#41; was administered at a dose of 600<span class="elsevierStyleHsp" style=""></span>mg &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m2&#41; on the 27th&#44; 34th&#44; 41st and 48th days after admission&#46; Cyclophosphamide &#40;arrowhead&#41; was administered in a single dose of 1000<span class="elsevierStyleHsp" style=""></span>mg on the 61st day after admission &#40;2nd day after readmission&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg for a week for 4 weeks&#44; started on the 158th day after admission&#44; followed by a dosage of 1200<span class="elsevierStyleHsp" style=""></span>mg 1 week later an then a maintenance dose of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks&#46; This dosage is still being continued&#46; We performed a total of 79 plasma exchange sessions&#46; The last three laboratorial test results were done on the 270th&#44; 340th and 466th days following first admission&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Atypical hemolytic-uremic syndrome &#40;aHUS&#41; is a rare&#44; life-threatening complement-mediated thrombotic microangiopathy&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> Approximately half of cases have mutations in complement proteins but only 12&#37; have 2 or more mutations&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> Eculizumab is nowadays considered first-line therapy for aHUS&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">A 33-year-old female with unremarkable past medical history presented with a 3-day history of decreased urine output&#46; Physical examination showed hypertension &#40;160&#47;90<span class="elsevierStyleHsp" style=""></span>mmHg&#41; and lower limbs edema&#46; Investigations revealed an acute thrombotic microangiopathy &#40;ATM&#41;&#44; hematuria and nephrotic proteinuria &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Daily plasmapheresis &#40;PMP&#41; was started immediately&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Investigations for secondary causes of ATM revealed a low ADAMTS 13 activity&#44; decreased complement C4&#44; C3&#44; C1q and C2 levels and positive serum cryoglobulins &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; Considering the hypothesis of an autoimmune disorder&#44; we started 3 daily pulses of 1000<span class="elsevierStyleHsp" style=""></span>mg methylprednisolone followed by oral prednisolone&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">PMP was stopped on the eighteenth day of admission &#40;D18&#41; due to normal platelet count during 3 consecutive days &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; On the D19 a renal biopsy was made&#46; It showed a &#8220;thrombotic microangiopathy with acute tubular necrosis&#8221; and &#8220;deposition of IgM&#44; C3 and C1q in the capillary wall&#8221;&#46; Due to increased hemolytic activity&#44; PMP was resumed on the D21&#46; On the D27&#44; rituximab was started to enhance immunosuppression&#46; PMP was stopped on the D35 based on the absence of schistocytosis&#44; hemoglobin stability and lactate dehydrogenase &#40;LDH&#41; normalization&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">On the D50&#44; LDH was high but hemoglobin and platelet count were stable&#46; A state of compensated hemolysis was assumed and the patient was discharged home&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Ten days later she was readmitted due to increased hemolytic activity &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; PMP was resumed and 1000<span class="elsevierStyleHsp" style=""></span>mg cyclophosphamide was given&#46; At that time ADAMTS13 and complement C4 levels were normal but complement C3 levels remained low&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">A genetic screening for mutations in complement regulatory proteins was made&#46; Two mutations were found in factor I &#40;C&#46; 452 A&#62;G&#44; pASN 151 Ser&#41; and C3 &#40;C193 A<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>C&#44; pLys 65 Gin&#41; proteins&#46; The process of eculizumab acquisition was lengthy&#44; wherefore this therapy was started only on the 98th day after readmission&#46; At that moment we were performing one PMP session&#47;week&#44; LDH remained high &#40;859<span class="elsevierStyleHsp" style=""></span>U&#47;L&#41; and moderate renal dysfunction &#40;creatinine 2&#46;08<span class="elsevierStyleHsp" style=""></span>mg&#47;dL and urea 60<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#41; and nephrotic proteinuria persisted &#40;5&#46;2<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg per week for 4 weeks followed by subsequent doses of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks since the 5th week&#46; Complete hematologic remission was attained 2 days after eculizumab initiation&#46; The patient was discharged home on the 105th day after readmission&#46; Four weeks later&#44; proteinuria was only 0&#46;6<span class="elsevierStyleHsp" style=""></span>g&#47;24<span class="elsevierStyleHsp" style=""></span>h&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Currently&#44; 10 months after first infusion&#44; the patient remains under biweekly administration of eculizumab&#46; Hematologic remission persists and there is a significant recover of renal function &#40;urea 43<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#44; creatinine 1&#46;27<span class="elsevierStyleHsp" style=""></span>mg&#47;dL&#41;&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Complement factor I &#40;CFI&#41; and C3 mutations account for 10&#37; and 4&#37; of the overall aHUS-associated mutations&#44; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> C3 mutations are among the ones with the poorest prognosis&#58; 75&#37; risk of death or end stage renal failure &#40;ESRF&#41; at 3&#8211;5 years follow up and 50&#37; risk of recurrence&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> CFI mutations have a 50&#8211;60&#37; risk of death and ESRF at 3&#8211;5 years follow up and 10&#8211;30&#37; risk of recurrence&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Both mutations present in our patient were previously reported&#46;<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a> The p&#46;Asn151Ser mutation causes a quantitative deficiency of factor I<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a> and the p&#46;Lys65Gin mutation weakens the affinity of C3b to complement factor H&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Despite the growing importance of eculizumab&#44;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#44;7</span></a> PMP remains the mainstay of treatment while waiting for the immunoglobulin&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> Nonetheless&#44; its benefit depends on the underlying genetic defect &#8211; only 25&#37; and 57&#37; of those with CFI and C3 mutations&#44; respectively&#44; achieve remission&#46;<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">8</span></a> In our patient&#44; PMP was critical to prevent further progression of renal failure and the development of other systemic involvement&#46; However&#44; as described by Loirat&#44;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> it was unable to achieve complete and sustained remission&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">In our case&#44; the confounding presence of low ADAMTS13&#44; C4&#44; C2 and C1q levels&#44; the presence of cryoglobulins and the existence of immune deposits in the glomerular capillary wall led to the misdiagnosis of a thrombotic thrombocytopenic purpura secondary to an autoimmune disease&#46; It explains the preference for glucocorticoids&#44; rituximab and cyclophosphamide in relation to eculizumab&#46;<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Eculizumab is nowadays considered first-line therapy for aHUS&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> It is a humanized monoclonal immunoglobulin IgG that targets C5 and blocks the uncontrolled generation of the cytotoxic membrane attack complex&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">10</span></a> When we started Eculizumab&#44; our patient was still PMP dependent despite the 79 PMP sessions&#46; Contrariwise&#44; complete hematologic remission was attained two days after first infusion and a remarkable recover of renal function and reduction of proteinuria was evident&#46; These findings reinforce the benefits of eculizumab in aHUS&#44; even in cases of severe renal involvement&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">In conclusion&#44; our case highlights the diagnostic challenge of aHUS and emphasizes the notion that isolated PMP is no longer the best therapeutic option in aHUS&#44; in which cases a prompt switch to eculizumab is mandatory&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest related to the contents of this article&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Ferreira E&#44; Oliveira N&#44; Marques M&#44; Francisco L&#44; Santos A&#44; Carreira A&#44; et al&#46; Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3&#46; Nefrologia&#46; 2016&#59;36&#58;72&#8211;75&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig&#46; 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 3462
            "Ancho" => 2390
            "Tamanyo" => 405309
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical course&#58; laboratory data and treatment&#46; Corticosteroid therapy was started with intravenous administration of methylprednisolone &#40;1000<span class="elsevierStyleHsp" style=""></span>mg&#47;day for 3 days&#41; followed by oral prednisolone and an initial dosage of 60<span class="elsevierStyleHsp" style=""></span>mg&#47;day&#46; This dosage was maintained until the 53rd day after admission&#44; with posterior tapering&#46; Rituximab &#40;arrows&#41; was administered at a dose of 600<span class="elsevierStyleHsp" style=""></span>mg &#40;375<span class="elsevierStyleHsp" style=""></span>mg&#47;m2&#41; on the 27th&#44; 34th&#44; 41st and 48th days after admission&#46; Cyclophosphamide &#40;arrowhead&#41; was administered in a single dose of 1000<span class="elsevierStyleHsp" style=""></span>mg on the 61st day after admission &#40;2nd day after readmission&#41;&#46; Eculizumab was administered at a dose of 900<span class="elsevierStyleHsp" style=""></span>mg for a week for 4 weeks&#44; started on the 158th day after admission&#44; followed by a dosage of 1200<span class="elsevierStyleHsp" style=""></span>mg 1 week later an then a maintenance dose of 1200<span class="elsevierStyleHsp" style=""></span>mg every 2 weeks&#46; This dosage is still being continued&#46; We performed a total of 79 plasma exchange sessions&#46; The last three laboratorial test results were done on the 270th&#44; 340th and 466th days following first admission&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">On admission</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hemoglobin &#40;g&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12&#8211;16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">White-cell count &#40;&#215;10<span class="elsevierStyleSup">3</span>&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4&#8211;10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Platelet count &#40;&#215;10<span class="elsevierStyleSup">3</span>&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">150&#8211;400&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral blood smear<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10 schistocytes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;2 schistocytes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Haptoglobin &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;0&#46;08&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;3&#8211;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Direct coombs tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urea &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">114&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15&#8211;38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Creatinine &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;52&#8211;1&#46;04&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sodium &#40;mmol&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">135&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">137&#8211;145&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Potassium &#40;mmol&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#46;5&#8211;5&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lactate dehydrogenase &#40;U&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2827&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">313&#8211;618&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">c-Reactive protein &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;1&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">URINALYSIS</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Protein &#40;mg&#47;dL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Leukocytes &#40;&#47;HPF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;5&#47;c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Red blood cells &#40;&#47;HPF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">28&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;2&#47;c&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Urinary protein to creatinine ratio &#40;mg&#47;mg&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;0&#46;15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1381851.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " colspan="3" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Additional studies</th></tr><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Result&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Normal range&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C3 &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;9&#8211;1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C4 &#40;g&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;02&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">0&#46;1&#8211;0&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CH50 &#40;U&#47;mL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23&#8211;46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">118&#8211;244&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C1q Inhibitor &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">197&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">180&#47;320&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">C2 &#40;mg&#47;L&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14&#8211;25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ADAMTS13 activity &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">40&#8211;130&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Anti-ADAMTS13 antibody &#40;U&#47;mL&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#60;15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serum cryoglobulins&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Auto-immune antibodies<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#44; Pregnancy test&#44; SPE&#44; Tumoral markers<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>&#44; HIV&#44; HBV&#44; HCV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&#47;Normal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Blood&#44; urine and stool cultures&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Upper endoscopy&#44; colonoscopy&#44; cervical&#44; thoracic and abdominopelvic CT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Irrelevant changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1381850.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar9005">Peripheral blood smear was done to evaluate presence of erythrocyte fragmentation and is reported as schistocytes count in a microscopic field at 100&#215; magnification&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Antinuclear antibodies&#44; extractable nuclear antigens&#44; anti-neutrophil cytoplasmic antibodies&#44; glomerular basement membrane&#44; rheumatoid factor&#44; cyclic citrullinated peptide&#44; anticardiolipin&#47;anti-&#946;2-glycoprotein&#44; Lupus anticoagulant&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Carcinoembryonic antigen&#44; carbohydrate antigen 19-9&#44; &#945;-fetoprotein&#44; cancer antigen 125&#44; neuron-specific enolase&#44; NSE&#46;</p> <p class="elsevierStyleNotepara" id="npar0020"><span class="elsevierStyleItalic">Abbreviations</span>&#58; ADAMTS13&#59; a disintegrin and metalloproteinase with a thrombospondin type 1 motif&#59; member 13&#46; CT&#59; computerized tomography&#46; HBV&#59; hepatitis B virus&#46; HCV&#59; hepatitis C virus&#46; HIV&#59; human immunodeficiency virus&#46; SPE&#59; serum protein electrophoresis&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Laboratorial results on admission and additional studies to establish the cause of the thrombotic microangiopathy&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of atypical uraemic syndrome in the era of eculizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "V&#46; Fremeaux-Bacchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/ckj/sfr177"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Kidney J"
                        "fecha" => "2012"
                        "volumen" => "5"
                        "paginaInicial" => "4"
                        "paginaFinal" => "6"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26069738"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Atypical hemolytic uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46; Loirat"
                            1 => "V&#46; Fr&#233;meaux-Bacchi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1750-1172-6-60"
                      "Revista" => array:5 [
                        "tituloSerie" => "Orphanet J Rare Dis"
                        "fecha" => "2011"
                        "volumen" => "6"
                        "paginaInicial" => "60"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21902819"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Actualizaci&#243;n en s&#237;ndrome hemol&#237;tico ur&#233;mico at&#237;pico&#58; diagn&#243;stico y tratamiento&#46; Documento de consenso"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Campistol"
                            1 => "M&#46; Arias"
                            2 => "G&#46; Ariceta"
                            3 => "M&#46; Blasco"
                            4 => "M&#46; Espinosa"
                            5 => "J&#46;M&#46; Griny&#243;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3265/Nefrologia.pre2012.Nov.11781"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nefrologia"
                        "fecha" => "2013"
                        "volumen" => "33"
                        "paginaInicial" => "27"
                        "paginaFinal" => "45"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23364625"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46; Bienaime"
                            1 => "M&#46;A&#46; Dragon-Durey"
                            2 => "C&#46;H&#46; Regnier"
                            3 => "S&#46;C&#46; Nilsson"
                            4 => "W&#46;H&#46; Kwan"
                            5 => "J&#46; Blouin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ki.2009.472"
                      "Revista" => array:6 [
                        "tituloSerie" => "Kidney Int"
                        "fecha" => "2010"
                        "volumen" => "77"
                        "paginaInicial" => "339"
                        "paginaFinal" => "349"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016463"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Novel C3 mutation p&#46;Lys65Gln in aHUS affects complement factor H binding"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46; Volokhina"
                            1 => "D&#46; Westra"
                            2 => "X&#46; Xue"
                            3 => "P&#46; Gros"
                            4 => "N&#46; van de Kar"
                            5 => "L&#46; van den Heuvel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00467-012-2183-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatr Nephrol"
                        "fecha" => "2012"
                        "volumen" => "27"
                        "paginaInicial" => "1519"
                        "paginaFinal" => "1524"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22669319"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A systematic review of eculizumab for atypical haemolytic uraemic syndrome &#40;aHUS&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Rathbone"
                            1 => "E&#46; Kaltenthaler"
                            2 => "A&#46; Richards"
                            3 => "P&#46; Tappenden"
                            4 => "A&#46; Bessey"
                            5 => "A&#46; Cantrell"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/bmjopen-2013-003573"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMJ Open"
                        "fecha" => "2013"
                        "volumen" => "3"
                        "paginaInicial" => "e003573"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24189082"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;M&#46; Legendre"
                            1 => "C&#46; Licht"
                            2 => "P&#46; Muus"
                            3 => "L&#46;A&#46; Greenbaum"
                            4 => "S&#46; Babu"
                            5 => "C&#46; Bedrosian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1208981"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2013"
                        "volumen" => "368"
                        "paginaInicial" => "2169"
                        "paginaFinal" => "2181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23738544"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Noris"
                            1 => "J&#46; Caprioli"
                            2 => "E&#46; Bresin"
                            3 => "C&#46; Mossali"
                            4 => "G&#46; Pianetti"
                            5 => "S&#46; Gamba"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2215/CJN.02210310"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin J Am Soc Nephrol"
                        "fecha" => "2010"
                        "volumen" => "5"
                        "paginaInicial" => "1844"
                        "paginaFinal" => "1859"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20595690"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0735109798005786"
                          "estado" => "S300"
                          "issn" => "07351097"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "Available at&#58; <span class="elsevierStyleInterRef" id="intr0005" href="http://www.uptodate.com/contents/treatment-and-prognosis-of-thrombotic-thrombocytopenic-purpura-hemolytic-uremic-syndromes-in-adults?source=search_result%26search=Treatment+of+thrombotic+thrombocytopenic+purpura-hemolytic+uremic+syndrome+in+adults%26selectedTitle=1~150">http&#58;&#47;&#47;www&#46;uptodate&#46;com&#47;contents&#47;treatment-and-prognosis-of-thrombotic-thrombocytopenic-purpura-hemolytic-uremic-syndromes-in-adults&#63;source&#61;search&#95;result&#38;search&#61;Treatment&#43;of&#43;thrombotic&#43;thrombocytopenic&#43;purpura-hemolytic&#43;uremic&#43;syndrome&#43;in&#43;adults&#38;selectedTitle&#61;1&#8764;150&#35;H30</span> &#91;accessed 14&#46;06&#46;14&#93;&#46; &#91;Updated 2014 May 14&#93;"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;A&#46; Kaplan"
                            1 => "J&#46;N&#46; George"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Uptodate"
                        "fecha" => "2014"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eculizumab&#58; a review of its use in atypical haemolytic uraemic syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "G&#46;M&#46; Keating"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40265-013-0147-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs"
                        "fecha" => "2013"
                        "volumen" => "73"
                        "paginaInicial" => "2053"
                        "paginaFinal" => "2066"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24249647"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003600000001/v2_201703300133/S2013251416000079/v2_201703300133/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35436"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Letters to the Editor"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003600000001/v2_201703300133/S2013251416000079/v2_201703300133/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251416000079?idApp=UINPBA000064"
]

Article information

ISSN: 20132514
Original language: English

DOI:10.1016/j.nefroe.2016.01.006

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	6	12	18
2024 October	43	56	99
2024 September	55	27	82
2024 August	75	69	144
2024 July	52	31	83
2024 June	62	33	95
2024 May	83	31	114
2024 April	68	27	95
2024 March	55	30	85
2024 February	47	36	83
2024 January	46	23	69
2023 December	37	31	68
2023 November	39	34	73
2023 October	37	24	61
2023 September	56	27	83
2023 August	27	26	53
2023 July	28	23	51
2023 June	62	21	83
2023 May	65	27	92
2023 April	49	17	66
2023 March	73	21	94
2023 February	55	15	70
2023 January	32	27	59
2022 December	71	31	102
2022 November	43	22	65
2022 October	58	36	94
2022 September	42	34	76
2022 August	42	54	96
2022 July	26	51	77
2022 June	33	41	74
2022 May	42	26	68
2022 April	32	55	87
2022 March	44	42	86
2022 February	31	35	66
2022 January	44	36	80
2021 December	56	33	89
2021 November	38	39	77
2021 October	35	37	72
2021 September	24	34	58
2021 August	36	42	78
2021 July	50	36	86
2021 June	47	35	82
2021 May	32	39	71
2021 April	58	38	96
2021 March	31	29	60
2021 February	32	27	59
2021 January	29	15	44
2020 December	31	30	61
2020 November	32	14	46
2020 October	34	20	54
2020 September	28	15	43
2020 August	26	11	37
2020 July	43	17	60
2020 June	20	21	41
2020 May	27	9	36
2020 April	24	25	49
2020 March	25	15	40
2020 February	34	19	53
2020 January	26	19	45
2019 December	36	19	55
2019 November	24	27	51
2019 October	19	11	30
2019 September	13	11	24
2019 August	18	15	33
2019 July	18	21	39
2019 June	17	14	31
2019 May	16	16	32
2019 April	34	34	68
2019 March	31	14	45
2019 February	20	14	34
2019 January	29	13	42
2018 December	158	42	200
2018 November	354	14	368
2018 October	350	19	369
2018 September	157	16	173
2018 August	171	18	189
2018 July	93	14	107
2018 June	106	24	130
2018 May	174	12	186
2018 April	171	14	185
2018 March	205	10	215
2018 February	87	5	92
2018 January	119	9	128
2017 December	95	5	100
2017 November	62	13	75
2017 October	36	8	44
2017 September	24	6	30
2017 August	25	8	33
2017 July	22	6	28
2017 June	33	8	41
2017 May	41	10	51
2017 April	32	10	42
2017 March	26	7	33
2017 February	22	7	29
2017 January	24	8	32
2016 December	28	7	35
2016 November	36	16	52
2016 October	48	6	54
2016 September	75	2	77
2016 August	46	0	46
2016 July	125	4	129
2016 June	79	0	79
2016 May	118	0	118
2016 April	52	0	52

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter